Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2080

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9A
Chunk 2080
---
armaceutical industry. He is currently a corporate advisor at Imunexus since 2020, Marinova since 2018, and GARDP (Switzerland)
since 2018. He was until recently the Australian representative of FIND (Switzerland) from 2018 to 2021 and a business development advisor
to the drug discovery company Biocurate from 2018 to 2020. Paul was previously the life sciences specialist at Austrade from 2014 to
2018, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research
in neglected tropical diseases, infectious diseases, autoimmune diseases, cancer and other therapeutic areas. Paul was the founder and
Executive Chairman of Bio-Link from 2005 to 2014, a privately owned biotechnology business development company. His work at Bio-Link
involved the commercialization of discovery, pre-clinical and early-stage clinical programs undertaken by Australian biotech companies
and medical research institutions. Paul has served on a number of Boards of Directors, and he is a Fellow of the Australian Institute
of Company Directors. The Board concluded that Mr. Field’s background and leadership experiences in the biotechnology industry
qualify him to be a member of the Board.

62

Significant Employees

We are a virtually managed pharmaceutical company
for which the significant employees are its officers.

Code of Ethics

Our Board has adopted a written code of business
conduct and ethics (“Code”) that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer and principal accounting officer or controller, or persons performing similar functions. We intend to post
on our website a current copy of the Code and all disclosures that are required by law in regard to any amendments to, or waivers from,
any provision of the Code.

Board Leadership Structure and Risk Oversight

Our Board has responsibility for the oversight
of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk
exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving
regular reports from board committees and members of senior management to enable our Board to understand our risk identification, risk
management, and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory,
cybersecurity, strategic, and reputational risk.

Board of Directors

Our Board consists of five members. Our business
and affairs are managed